When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Optic neuritis

Last reviewed: 12 Dec 2025
Last updated: 06 Jun 2024

Summary

Definition

History and exam

Key diagnostic factors

  • periorbital/retro-ocular pain
  • loss of visual acuity with scotoma
  • color desaturation/loss of color vision
  • relative afferent papillary defect (RAPD)
Full details

Other diagnostic factors

  • optic disk swelling
  • neurologic abnormalities of multiple sclerosis
  • Uhthoff phenomenon
  • phosphenes
  • Pulfrich phenomenon
  • perivenous sheathing
Full details

Risk factors

  • age 30 to 50 years
  • female sex
  • white ethnicity
  • HLA-DRB1*1501 genotype
  • risk factors for multiple sclerosis (MS; Epstein-Barr virus [EBV] infection, vitamin D deficiency, and smoking)
  • childhood in higher latitudes
  • presence of autoimmune disease
  • exposure to infectious diseases, such as Lyme disease and syphilis
Full details

Diagnostic tests

1st tests to order

  • MRI - brain
  • CBC
  • ESR
  • C-reactive protein
  • venereal disease research laboratory (VDRL)
  • aquaporin-4 (AQP4) antibody, myelin oligodendrocyte glycoprotein (MOG) antibody, and collapsin response mediator protein 5 (CRMP5) antibody
  • uric acid
  • serum ACE
  • ANA
  • B12 and folate
Full details

Tests to consider

  • Lyme titer
  • cerebrospinal fluid analysis
Full details

Treatment algorithm

ACUTE

acute episode

ONGOING

coexisting inflammatory diseases (e.g., NMOSD, MOGAD, SLE or sarcoidosis)

Contributors

Authors

Cris S. Constantinescu, MD, PhD

Chair of Neurology Emeritus

Academic Unit of Mental Health and Clinical Neuroscience

University of Nottingham

Nottingham

UK

Attending Neurologist

Professor of Neurology

Cooper Neuroscience Institute

Camden

New Jersey

Divulgaciones

CSC has received research support or consultancy fees from Biogen, GW, Merck, Morphosys, Novartis, Roche, Sanofi-Pasteur, MSD, and Teva. CSC is an author of a number of references cited in this topic.

Thomas M. Bosley, MD
Thomas M. Bosley

Knights Templar Eye Foundation Professor of Ophthalmology

Wilmer Eye Institute

Johns Hopkins University

Baltimore

MD

Divulgaciones

TMB declares that he has no competing interests.

Revisores por pares

Gus Gazzard, MA, MBBChir, MD, FRCOphth

Consultant Ophthalmic Surgeon

King's College Hospital

Honorary Research Fellow

Institute of Ophthalmology

London

UK

Divulgaciones

GG declares that he has no competing interests.

John Selhorst, MD

Professor

Department of Neurology and Psychiatry

Saint Louis University

St. Louis

MO

Divulgaciones

JS declares that he has no competing interests.

Efstratios Mendrinos, MD

Department of Ophthalmology

Geneva University Hospitals

Geneva

Switzerland

Divulgaciones

EM declares that he has no competing interests.

Jonathan Smith, MD

Specialist Registrar in Ophthalmology

Royal Victoria Infirmary

Newcastle

UK

Divulgaciones

JS declares that he has no competing interests.

Peter Sguigna, MD

Assistant Professor

Department of Neurology

The University of Texas

Southwestern Medical Center

Dallas

TX

Divulgaciones

PS has received grant support from National Multiple Sclerosis Society, International Progressive Multiple Sclerosis Alliance, National Institute of Health (NIH), Center for Translational Medicine, Physician Scientist Training Program, and Department of Defense (DOD). He has received research support from Genentech, Clene Nanomedicine, and Patient Centered Outcomes Research Institute. He has received consulting fees from Medical Logix LLC, Genentech, EMD Serono, Horizon Therapeutics, and Bristol Myers Squibb. He is the inventor on a patent for OCT technology that is held by UT Southwestern Medical Center.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Petzold A, Fraser CL, Abegg M, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022 Dec;21(12):1120-34. Resumen

American Academy of Ophthalmology. Optic neuritis - 2012. Jul 2012 [internet publication].Texto completo

Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581-8. Resumen

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73.Texto completo  Resumen

Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010 Aug;17(8):1019-32.Texto completo  Resumen

Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015 Aug 14;(8):CD001430.Texto completo  Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Optic neuritis images
  • Diferenciales

    • Lyme disease
    • Syphilis
    • HIV infection
    Más Diferenciales
  • Guías de práctica clínica

    • Optic neuritis
    • Guidelines on diagnosis and management of neuromyelitis optica
    Más Guías de práctica clínica
  • Folletos para el paciente

    Lyme disease

    Multiple sclerosis

    Más Folletos para el paciente
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad